News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SANUWAVE, Inc. Provides Update On Patient Enrollment - Over 75 Percent Now Enrolled In Pivotal Dermapace Clinical Trial


1/29/2014 8:50:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALPHARETTA, Ga., Jan. 29, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that it has enrolled over seventy-five percent (75%) of the minimum required patients in the Phase III supplemental clinical trial evaluating the dermaPACE® device on patients with diabetic foot ulcers. The clinical trial is designed to enroll a minimum of 90 patients; which is on track to occur in the first quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES